Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP916679.RACX4UPvEsY_yVxxqSm29h9FX1jc2eHtbMDQQK99EPATQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP916679.RACX4UPvEsY_yVxxqSm29h9FX1jc2eHtbMDQQK99EPATQ130_assertion type Assertion NP916679.RACX4UPvEsY_yVxxqSm29h9FX1jc2eHtbMDQQK99EPATQ130_head.
- NP916679.RACX4UPvEsY_yVxxqSm29h9FX1jc2eHtbMDQQK99EPATQ130_assertion description "[To identify the patients most likely to benefit from such therapies, EGFR or KRAS gene mutation tests are mandatory, respectively, in NSCLC and in CRC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP916679.RACX4UPvEsY_yVxxqSm29h9FX1jc2eHtbMDQQK99EPATQ130_provenance.
- NP916679.RACX4UPvEsY_yVxxqSm29h9FX1jc2eHtbMDQQK99EPATQ130_assertion evidence source_evidence_literature NP916679.RACX4UPvEsY_yVxxqSm29h9FX1jc2eHtbMDQQK99EPATQ130_provenance.
- NP916679.RACX4UPvEsY_yVxxqSm29h9FX1jc2eHtbMDQQK99EPATQ130_assertion SIO_000772 21837660 NP916679.RACX4UPvEsY_yVxxqSm29h9FX1jc2eHtbMDQQK99EPATQ130_provenance.
- NP916679.RACX4UPvEsY_yVxxqSm29h9FX1jc2eHtbMDQQK99EPATQ130_assertion wasDerivedFrom befree-2016 NP916679.RACX4UPvEsY_yVxxqSm29h9FX1jc2eHtbMDQQK99EPATQ130_provenance.
- NP916679.RACX4UPvEsY_yVxxqSm29h9FX1jc2eHtbMDQQK99EPATQ130_assertion wasGeneratedBy ECO_0000203 NP916679.RACX4UPvEsY_yVxxqSm29h9FX1jc2eHtbMDQQK99EPATQ130_provenance.